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Absence of Mutations in PAX6 Gene in Three Cases of 
Morning Glory Syndrome Associated with Isolated 
Growth Hormone Defi ciency
ABSTRACT
Morning glory syndrome (MGS) is a congenital optic disc dysplasia often as-
sociated with craniofacial anomalies, especially basal encephalocele and hy-
popituitarism. Clinical signs are varied and often occult. The PAX6 gene is 
involved in ocular morphogenesis and is expressed in numerous ocular tissues 
during development especially in the developing central nervous system. The 
aim of the present study is to evaluate PAX6 in MGS associated with isolated 
growth hormone defi ciency. Three pre-pubertal males (A, B and C) with MGS 
and short stature due to growth hormone defi ciency, treated with recombinant 
human growth hormone with limited response, were reported. Two of them 
had basal encephalocele. Coding and non-coding sequences corresponding of 
PAX6 different transcripts were analyzed by direct sequencing. Nucleotide vari-
ations causing putative aminoacid change were not observed. Patient A pre-
sented the new IVS2+9G>A transition, whereas patients A and C were 
heterozygous for known single nucleotide polymorphisms (SNP) within the in-
tron 4. In addition, two SNP heterozygoses were observed for patient C in both 
intron 9 and 13. Sequencing also revealed several nucleotide variations in pa-
tient B. Two heterozygoses for known polymorphisms were identifi ed along 
with a novel C>A nucleotide change in intron 4. This patient also presented a 
low number on the TG repeat in intron 9 and a new IVS11+33A>T transversion. 
Gene regulation and transcription of PAX6 are complex processes; there are 
two major protein isoforms, PAX6(-5a) and PAX6(+5a), and nine transcripts de-
scribed. Furthermore, extra transcription regulatory elements have been postu-
lated within PAX6 introns. Considering that neither population distributions on 
PAX6 polymorphism nor their linkeages with diseases have been reported, a 
functional effect due to alterations described here cannot be discarded. (Arq 
Bras Endocrinol Metab 2008; 52/8:1221-1227)
Keywords: Encephalocele; Growth hormone; Morning glory syndrome; PAX6 
gene; Short stature
RESUMO
A Ausência de Mutações no Gene PAX6 em Três Casos de Síndrome de Morn-
ing Glory Associada à Defi ciência Isolada de Hormônio do Crescimento.
A síndrome de Morning Glory (SMG) é uma displasia óptica congênita asso-
ciada a anomalias craniofaciais, principalmente encefalocele basal e hipopitu-
itarismo. Os sinais clínicos são variados e muitas vezes ocultos. O gene PAX6 
está envolvido na morfogênese ocular e se expressa em vários tecidos ocu-
lares durante o desenvolvimento do sistema nervoso central. O objetivo deste 
estudo foi avaliar o gene PAX6 na SMG associada com defi ciência isolada de 
hormônio de crescimento. Foram relatados três pacientes pré-púberes (A, B e 
C) com SMG e baixa estatura por defi ciência de hormônio de crescimento trat-
ados com hormônio de crescimento recombinante humano. As seqüências 
codifi cadoras e não-codifi cadoras correspondentes ao PAX6 em diferentes 
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less, the molecular mechanisms mediating the RPCs 
retinogenic potential have not been established yet.
Kioussi and cols. (8) showed that PAX6 is also 
implicated in the development of both, Rathke pouch 
and early anterior pituitary gland, whereas its expres-
sion controls the boundaries of somatotrope, lacto-
trope, and thyrotrope cell types. In the absence of 
PAX6 the thyrotrope cells lineage increases markedly 
along with the decrease of somatotrope and lacto-
trope cells. 
The aim of the present study is to evaluate molecular 
features in PAX6 gene in three patients with MGS and 
isolated growth hormone defi ciency.
SUBJECTS AND METHODS
Case reports
Three patients with MGS, two from Federal University 
of Sao Paulo (Unifesp/EPM – Brazil) (A and B) and one 
from University of Campinas (Unicamp – Brazil) (C) 
were referred to the Pediatric Endocrine Clinic, due to 
short stature. The ophthalmological exam, including a 
retinography, showed typical abnormalities of the MGS, 
comprising an optical disk with an enlarged choanoid 
and cupped aspect, with a pink pigmentation and a cen-
tral white mass which hid the way of the vessels at the 
bottom of the disk. The disk was surrounded by a little 
elevated grey ring, with irregular borders and mixed with 
colored areas. The vessels were multiple, thin and radia-
ted (Figure 1). 
INTRODUCTION
Morning glory syndrome (MGS) is a congenital malformation of the optic disc characterized by an 
enlarged, funnel-shaped optic disc and an elevated pig-
mented peripapillary tissue annulus, fi rstly described in 
1970 and named by Kindler (1) due to a resemblance to 
the fl ower of the same name. MGS can be associated 
with basal encephalocele and hypopituitarism. Basal 
(meningo) encephalocele is an sporadic and occult mal-
formation, described in 67,7% of MGS patients, usually 
associated with midline defects, such as cleft palate and 
corpus callosum agenesis, optic disc and other brain ano-
malies, and hormonal disturbance (2-5).
Azuma and cols. (6) identifi ed PAX6 (paired box 6) 
gene (11p13) mutations in pedigrees with optic nerve 
malformations, including coloboma, morning glory disc 
anomaly, optic nerve hypoplasia/aplasia and persistent 
hyperplastic primary vitreous. Some of these mutations 
may affect transcriptional repression of the PAX2 pro-
moter mediated by PAX6. In view of the detection of 
PAX2 gene mutations in papillorenal syndrome, it has 
been suggested that modifi cations in PAX2 function, as 
a result of PAX6 mutations, may affect some phenotypic 
expressions including those of the optic nerve malforma-
tions. Furthermore, Marquardt and cols. (7) demon-
strated that PAX6 controls the transcriptional activation 
of retinogenic basic helix-loop-helix factors that predis-
poses subsets of multipotent retinal progenitor cells 
(RPCs) towards different retinal cell fates, thereby medi-
ating the full retinogenic potential of RPCs. Nonethe-
transcritos foram analisadas por seqüenciamento direto. Variações nucleo-
tídeas com trocas pontuais de aminoácidos não foram encontradas. O paciente 
A apresentou uma transição nova IVS2+9G>A, enquanto os pacientes A e C 
foram heterozigotos para um polimorfi smo (SNP) no íntron 4. Ainda, dois SNPs 
em heterozigose nos íntrons 9 e 13 foram observados no paciente C. O seqüen-
ciamento também mostrou várias variações nucleotídeas no paciente B. Dois 
SNPs conhecidos com a alteração nucleotídea nova C>A no íntron 4 foram 
observados em heterozigose. Este paciente também apresentou um baixo 
número de repetições TG no íntron 9 e uma nova transversão IVS11+33A>T. A 
regulação e a transcrição do gene PAX6 são um processo complexo; existem 
2 isoformas principais da proteína, PAX6(-5a) e PAX6(+5a) e 9 transcritos 
descritos. Considerando que nem a distribuição de SNPs no PAX6 e nem as 
suas ligações com as doenças foram relatadas, um defeito funcional devido 
às alterações descritas não pode ser descartado. (Arq Bras Endocrinol Metab 
2008; 52/8:1221-1227)
Descritores: Encefalocele; Hormônio do crescimento; Morning glory syndrome; 
Gene PAX6; Estatura baixa
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All patients were normally delivered at full term, af-
ter uneventful pregnancies. Patients A and B had unre-
markable medical histories, but patient C presented 
failure to thrive and delayed psychomotor development, 
beginning at one year of age. None of them had family 
history of hormonal disorders or congenital anomalies. 
Clinical and laboratory data are summarized in Table 1. 
During follow-up, all patients showed low growth 
rate (below 3 cm/year) and a hormonal profi le compat-
ible with isolated growth hormone defi ciency (Table 1). 
They had no symptoms of diabetes insipidus. A mag-
netic resonance imaging (MRI - Phillips Gyroscan 1,5T), 
with sagittal and coronal images from the sellar region, 
was obtained on the T1 weighted spin echo (T1WSE) 
sequence before and after the paramagnetic contrast me-
dium intravenous administered, and in T2 weighted spin 
echo sequence. It was observed inferior and posterior 
herniation of the sella content through the sella fl oor 
defect towards the sphenoidal sinus (basal encephalo-
cele) in patients A and B. Patient C did not present en-
cephaloceles, but he had a hypoplastic adenohypophysis, 
ectopic neurohypophysis with a normal stalk (Figure 2).
Figure 2. Magnetic resonance imaging (MRI) from patient A: 
2A: MRI TSE sequencing, T1-ponderated, sagittal plane, show-
ing inferior and posterior herniation of the sella content 
through the sella fl oor defect towards the sphenoidal sinus 
(basal encephalocele); 2B: MRI TSE sequencing, T1-ponder-
ated, coronal plane, after contrast, showing inferior hernia-
tion and deformity of optic chiasm, as well as posterior 
herniation of sella content towards the sphenoidal sinus; 2C: 
MRI, T2-ponderated, coronal plane, showing sella fl oor de-
fect, inferior herniation of optic chiasm, and posterior hernia-
tion of sella content towards the sphenoidal sinus.
Table 1. Clinical and laboratory data from three patients with 
Morning Glory Syndrome and isolated growth hormone defi -
ciency.
Patient A Patient B Patient C
Birth weight (kg) 2.82 2.80 2.85
Birth length (cm) 49.0 49.0 46.0
Strabismus + – +
Ocular hypertelorism – – +
Microphthalmia – + –
Visual acuity 20/400 20/400 15/400
At endocrine evaluation
Age (years-old) 8.0 12.2 9.0
Weight in Kg (SDS) 16.2 (-4.1) 27.6 (-2.4) 20.0 (-2.7)
Height in cm (SDS) 100.0 (-5.2) 128.5 (-3.0) 107.0 (-4.6)
Pubertal stage Tanner I Tanner I Tanner I
GH 1 (ng/mL)1 3.6 0.9 1.9
GH 2 (ng/mL)2 0.2 0.5 1.6
IGF-1 (ng/mL)3 67.0 115.0 43.0
IGFBP-3 (ng/mL)4 1,530 2,650 1,421
TSH (IU/L)5 3.8 1.8 4.8
Free T4 (ng/dL)6 1.1 1.1 1.2
Cortisol (mcg/dL)7 13.4 20.4 17.0
Bone age (Greulich-Pyle) 5.6 11.0 7.0
SDS= standard-deviation score; GH 1 = growth hormone after 0.15 mg/m2 of oral 
clonidine; 1 normal range = NR = > 7.0 ng/mL; GH 2 after 0.1 IU/kg crystalline 
insulin i.v.; 2 NR = > 7.0 ng/mL; 3 NR = 23.0 to 392.0 ng/mL; 4 NR = 1,250 to 6,350 ng/
mL; 5 NR = 0.4 to 6.0 IU/L; 6 0.8 to 2.0 ng/dL; 7 NR = 5.0 to 25.0 mcg/dL
Figure 1. 1A: The morning glory fl ower; 1B: Left eye retinogra-
phy from patient A with a morning glory aspect (Figure 1B 
was gently offered by Prof. Paulo Mitsuru Imamura, from De-
partment of Ophthalmology, Unifesp/EPM).
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Patient A started growth hormone replacement 
therapy (rhGH) at age of 10, at a dose of 0.03 mg/kg/
day, by subcutaneous injections, presenting with a 
growth rate of 11.5 cm/year during the fi rst year of 
treatment and a progressive decrease, onward to 5 cm 
and 3 cm, respectively at the 2nd and 3rd year of treat-
ment, regardless of an increase in the rhGH dosage. Pa-
tient B started rhGH at the age of 13 at a dose of 0.03 
mg/kg/day. During the fi rst two years of therapy the 
growth rate was respectively 12 cm/year and 5.0 cm/
year, even though rhGH dosage was increased up to 
0.05 mg/kg/day at the second year. Patient C was start-
ed on rhGH at the age of nine, at a dose of 0.05 mg/
kg/day. During the fi rst two years of treatment, growth 
rate was respectively 6.5 cm/ year during the fi rst year 
and subsequently 5 cm/year. It is worth noting that dur-
ing the second year the dosage of growth hormone was 
increased to 0.075 mg/kg/day. No other hormonal de-
fi ciencies were observed. Patient C showed a progressive 
ocular dysfunction and became blind at the right eye. 
The replacement therapy was discontinued after the 
third year. The presence of anti-GH antibodies was ruled 
out in the three cases. Currently, patients A and C are 
almost near fi nal height and end up very short (height 
scores below -2 SDS). Patient B is still under rhGH ther-
apy despite poor response.
Molecular studies
Genomic DNA was isolated from blood leukocytes us-
ing standard techniques (9). All fourteen coding and 
non-coding exons of the human PAX6 gene were ampli-
fi ed by PCR using specifi c primers listed in Table 2. PCR 
reactions were carried in 50 µl containing: ~500 ng ge-
nomic DNA, 10% DMSO, 200 µM each dNTP, 20 
pmoles of each primer, 1xTaq buffer solution (Invitro-
gen, CA. USA) and 1.5 units of recombinant Taq DNA 
polymerase (Invitrogen, CA. USA). In general, cycling 
profi les were: 94 °C for 5 min; 94 °C for 1 min, Ta (°C) 
specifi c for each primer pair (Table 2) for 1 min, 72 °C 
for 1 min (30 cycles); and a fi nal extension step of 72 C 
for 5 min. PCR products were purifi ed with Wizard SV 
Gel and PCR Clean-UP System (Promega, Madison, 
WI, USA) and directly sequenced in both sense and an-
tisense orientations using amplifi cation primers; for long 
fragments, additional sequencing with an internal primer 
was performed (Table 2). Sequencing reactions were 
conducted using Big DyeTM Terminator Cycle Sequenc-
ing Kit V3.1 Ready Reaction (ABI PRISM / PE Biosys-
tems, Foster City, CA, USA) and DNA sequences were 
obtained in an ABI PRISM® 3700 DNA Analyzer (ABI 
PRISM/PE Biosystems, Foster City, CA, USA). The 
electropherograms were analyzed by Chromas Lite pro-
gram (free-software). Sequencing data obtained in this 
study was compared to the PAX6 gene sequence de-
scribed by International Human Genome Consortium 
(GENEBANK access # NC_000011) using the Gene-
Runner v3.05 (free-software).
Table 2. Primers used for PAX6 PCR amplifi cations and se-
quencing.
Region Primer sequence (5’-3’)1 Ta2 (°C)
Exon 1
s - TCATATTCAAACAAACGGACC
as - AAGAGTGTGGGTGAGGGAAGT 
57
Exon 2
s - TTATCTCTCACTCTCCAGCCG
as – GGAGACCTGTCTGAATATTGC
55
Exon 3
s - TGTGGGTGTAATGCTGGGACT
as - GAATATCCCCAATCTGTTTCCC
61
Exon 4
s - TTGGGAGTTCAGGCCTACCT 
as - CCAGTATCGAGAAGAGCCAAG
58
Exon 53 
region 1
s - TCAAACTTGACGTGCAGCTAG
as - ATAGTGTTCCCCATCCCTCCT
58
Exon 5 
region 2
s - CTAAGGTTGGACCACAGGGAT
as - TCCAGAAATGTTTCCATCACC
59
Exon 5 
region 3
s - ACATACTGGCTGCTCTGGTTG
as - CTACAGCCATAACCCCAGCAG 
59
Exon 5 
region 4
s - TGGCTGCAGTGTTTATGAAGA
as - CACCACCGAGCTGATTCACTC
58
Exon 5 
region 5
s - TCTTCTTCCTCTTCACTCTGC
as - TGAAAGAGATAGGGAAGGATG
55
Exons 6-7
6 s - ATTTATCTACTTCGTTTTGATGC
7 as - AGAGGGTGGGAGGAGGTAAAG
56
Exon 6 
seq4
s - TGGACAATCAAAACGTAAGCT -
Exon 8
s - AGCTGAGATGGGTGACTGTGT
as - AAGGGATGCACATATGGAGAG
58
Exon 9
s - GGGAATGTTTTGGTGAGGCT
as - ACCTCCAACCAATTCCCTTTA
60
Exon 9 
seq4
s - ACGGAGAAGATTCAGATGAGG -
Exon 10
s - GGAACCAGTTTGATGCACAGT
as - GCAGCAGAGCATTTAGCAGAC
58
Exons 
11-12
s - GTCTGCTAAATGCTCTGCTGC
as - AGCTCTCAAGGGTGCAGACAC
60
Exon 13
s - TGGCTGTGTGATGTGTTCCTC
as - AGAAAACTTGCAGTCTCAGGC
58
Exon 14
s – CCATGTCTGTTTCTCAAAGGGA
as – CCCCAGTGGTACAATACAGGA
59
1s = sense; as = antisense; 2Ta = annealing temperature used for PCR; 3The exon 5 
was divided in 5 fragments due its long size; 4Primers used for sequencing only.
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RESULTS
Genomic sequences corresponding to PAX6 different 
transcripts were analyzed by direct sequencing. PAX6 
gene is transcribed into nine different transcripts. They 
differ to each other by alternative splicings of exons 1-4 
in the 5’-UTR. Whereas sequencing of PAX6 coding 
DNA did not reveal any putative aminoacid change, new 
variations and several already known SNPs were found in 
non-coding regions (Table 3). 
Patient A was found to be heterozygous for a novel 
IVS2+9G>A transition in intron 2. Two novel polymor-
phisms were observed for patient B: transversions 
g.14807C>A and IVS11+33A>T located in intron 4 and 
11, respectively. Conversely, patient C did not present 
any novel nucleotide variation.
Patients A and C showed heterozygosis for the 
g.14592C>A (SNP-rs694617) transversion and also for 
the indel g.15449_15450insG (SNP-rs5790867) both 
located in intron 4. In addition, patient C presented the 
g.24214A>T (SNP-rs2239789) and IVS13+43T>G 
(SNP-rs3026393) transversions in intron 9 and 13, re-
spectively. 
Several SNPs were also observed for patient B. The 
heterozygosis for the nucleotide changes g.14806T>G 
(SNP-rs3026368) and g.15003A>G (SNP-rs3026369) 
within intron 4 were found, additionally only this patient 
was homozygous for +G allele at the indel 
g.15449_15450insG (SNP-rs5790867). 
An intron 9 microsatellite formed by TG Short Tan-
dem Repeat (STR) was also investigated. Normally, 
PAX6 alleles bear a sequence of (TG)19-29 repeats inter-
rupted by a GG dinucleotide and followed by a (TG)7 
repeat. Patients A and C were heterozygous for (TG)19/21 
– GG – (TG)7 sequences, however patient B was 
heterozygous for (TG)16/19 repeats with absence of the 
intercalated GG dinucleotide and the last (TG)7 repeats 
(Table 3). 
DISCUSSION
We reported three patients with ocular lesion compatible 
with MGS associated with isolated growth hormone de-
fi ciency with a limited response to rhGH replacement 
and PAX6 gene molecular features.
Neither hereditary nor pregnancy possible events ac-
cording to published data so far (10) had infl uenced 
MGS in the cases described here. Reports on sex ratio 
have been controversial, but some authors consider MGS 
to be more commom in females (10,11). Nevertheless 
all patients studied in the present paper were males.
Likewise, the three described patients had bilateral 
disease whereas MGS is frequently unilateral and non-
progressive. In addition, all patients became blind dur-
ing the follow-up, which is a rare event (10-13). It was 
impossible to determine if rhGH have had any infl uence 
on the worsening the eye disease, since there are no re-
ports available on this subject.
The patients in this report had mild midline defects 
such as hypertelorism (patient C), strabismus (patients A 
and C), and microphthalmia (patient B), however no 
signs of systemic diseases or any hormonal defect other 
Table 3. PAX6 sequence variation dada in three patients with morning glory syndrome and isolated growth hormone defi -
ciency.
intron 2
(IVS+9G>A) Intron 4
Intron 9
(STR-(TG)n)
Intron 9
Intron 11
(IVS11+33T>A)
Intron 13
Patient A G/A C/A T/T | C/C | A/A –G/+G (TG)19/21 – GG – (TG)7 A/A T/T T/T
Patient B G/G C/C T/G | C/A | A/G +G/+G (TG)16/19 A/A T/A T/T
Patient C G/G C/A T/T | C/C | A/A –G/+G (TG)19/21 – GG – (TG)7 A/T T/T T/G
Genomic 
position1
g. 7743G>A g. 14592C>A
g. 14806T>G | g. 14807C>A | 
 | g. 15003A>G
g. 15449->G g. 24083–g.24156 g.24214A>T g.24943T>A g.27895T>G
SNP2 not described rs694617
rs3026368 | 
not described | rs3026369
rs5790867 rs105252664 rs2239789 not described rs3026393
Frequency3 – 100% C – | – | – – – 50%A | 50% T – –
1Based in Ensembl – ENSG00000007372 (http://www.ensembl.org/Homo_sapiens); 2SNP number at NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP); 3SNP Frequency 
for several populacional groups; NCBI SNP database dada (http://www.ncbi.nlm.nih.gov/SNP); 4SNP describe as an in del (TG)1–10/-; therefore, normal alleles are (TG)19/29 
– CG – (TG)7
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than growth hormone defi ciency was remarked. Most 
cases of MGS are considered as isolated ocular abnor-
malities, but other malformations of the skull, facial, 
mainly midline defects, and central nervous system may 
occur (13). Associations with genetic syndromes and 
systemic diseases, including growth hormone defi ciency 
have also been reported (10,11). 
The hormonal defi ciency described in the other re-
ported cases is usually secondary to the compression of 
the pituitary gland by basal encephaloceles (14,15), but 
the natural course of the hypothalamic-pituitary dys-
function is at present still unclear. In our patients the 
causative factors were not clearly identifi ed. There is al-
ways a possibility that the growth hormone defi ciency 
could have occurred by chance. Nonetheless, the growth 
hormone defi ciency was not an isolated fact, and the pa-
tients did not have a good response to rhGH treatment, 
according to Ranke predictive models (16). There are 
no reports about other patients with MGS that had been 
treated with rhGH. Our patients had an acceptable re-
sponse at the beginning of the treatment but a normal 
growth rate could not be maintained, even with a higher 
dose than usual, during the subsequent years. GH, IGF-
1 and IGFBP-3 profi le did not point out a possible GH 
resistance. 
Regarding pituitary function, there was no progres-
sion of the hormonal defi ciencies, even in what concerns 
diabetes insipidus, considered a common event associ-
ated with MGS (10,13).
In order to verify if mutations on PAX6 gene could 
explain MGS phenotypes in those patients, we proceed 
with PAX6 sequence analysis. However, nucleotide al-
terations were not identifi ed in the protein coding se-
quence. PAX6 gene sequence analysis revealed several 
SNPs and at last one non-described heterozygous nucle-
otide was found in patients A and B. PAX6 protein is a 
transcription factor with important functions in the de-
velopment of eyes and central nervous tissues (17). The 
most abundant transcripts present 13 or 14 exons de-
pending on the inclusion or not of exon 5a. Therefore, 
there are two major PAX6 isoforms: PAX6(-5a), with 
422 amino acids, and PAX6(+5a), with 436 amino acids 
resulting from the insertion of a 14 amino acid-long se-
quence in the paired domain (18). Furthermore, alter-
native splicings are responsible for the production of 
nine different transcripts, which results from distinct 
exon combinations in 5’UTR and are transcribed in dif-
ferent tissues, although most of them are mainly found 
in the cerebral tissue. Evidences suggest that the com-
plexity of PAX6 transcription, regulation and expression 
is probably important for its multiple functions, whereas 
the spatiotemporal regulation and the expression of 
PAX6 isoforms are still not well understood. Recently, 
some elements corresponding to transcription regulato-
ry consensus sequences have been described within 
PAX6 introns, suggesting that intronic sequences are 
important for the regulation maintenance in a high con-
served gene (19). Concerning to SNPs already described, 
there is only one paper that failed to demostrate the link-
age of SNP rs2239789 to myopia (20). In addition to 
the SNPs identifi ed in the present study and those al-
ready described, PAX6 gene has a TG microsatellite 
within intron 9. Dinucleotide repeats located in introns 
are not generally considered to have functional roles in 
gene expression. However, their highly variable nature 
suggests a role as modifi ers of RNA splicing. To support 
this idea, there is the fi nding that a variable number of 
TG repeats present in intron 8 of CFTR gene contrib-
utes to phenotype diversity in Cystic Fibrosis by forming 
RNA secondary structures that alter exon 9 splicing pro-
cess (21). Linkages of TG repeats within intronic regions 
of different genes, including PAX7 which belongs to the 
same PAX6 gene family, have been described in a few 
diseases (22-24). Therefore, it is possible that nucleotide 
alterations within introns might have effects in transcript 
productions. Taking this hypothesis, PAX6 gene altera-
tions found in patients A, B and C, whereas they cannot 
be considered as mutations, they could be probably as-
sociated with the phenotype. Considering that popula-
tion studies on the distribution of PAX6 gene SNPs are 
not yet available in the database, a well conducted evalu-
ation on normal individuals using novel and described 
SNPs must be performed to test this hypothesis. In sum-
mary, a functional effect of novel and known alterations 
described here for MGS patients cannot promptly be re-
jected. 
Although MGS is usually a non-progressive untreat-
able disease, accurate diagnosis is important due to its 
association with systemic anomalies and increased inci-
dence of retinal detachment (13). Undoubtedly, the dis-
ease manifests with a broad spectrum of characteristics, 
and we might have faced a new expression of the disor-
der. Notwithstanding, dysplasic optic disc should always 
be an alert for physicians to the occurrence of an en-
cephalocele (25). Emphasis on these systemic and ocular 
associations may prompt early detection, and result in 
benefi t from treatment, as well as could possibly be a 
clue for a better understanding of the disease under the 
molecular genetics aspects in order to develop a model 
for further studies. 
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